13 h. ago China–Cartel Nexus: The Liquidity Architecture Transforming the Global Drug Economy

China–Cartel Nexus: The Liquidity Architecture Transforming the Global Drug Economy  New Lines Institute

Events

9 d. ago China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including...

Economics

2 w. ago How China went from generic drug factory to biomedicine innovator

China’s pharmaceutical industry is on the brink of enormous growth and transformation. In just a few years, it has moved on from being the world’s cheapest source of active pharmaceutical ingredients to becoming a major hub for pharmaceutical innovation – a place where new, more effective drugs are born. It is now the second-largest developer of drugs, trailing only the United States. In the global drug development pipeline, China’s growth rate is phenomenal, leaping from 3 per cent in 2013 to...

Events

2 w. ago How China engineered the rapid rise of its drug innovation industry

China’s pharmaceutical industry is on the brink of enormous growth and transformation. In just a few years, it has moved on from being the world’s cheapest source of active pharmaceutical ingredients to becoming a major hub for pharmaceutical innovation – a place where new, more effective drugs are born. It is now the second-largest developer of drugs, trailing only the United States. In the global drug development pipeline, China’s growth rate is phenomenal, leaping from 3 per cent in 2013 to...

Events

2 w. ago China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Chinese drug maker 3SBio plans to raise HK$3.12 billion (US$401 million) by selling a 4.14 per cent stake in the company to fund clinical research in China and the US and expand the global reach of its drug portfolio. The Shenyang-based biopharmaceutical firm has agreed to sell 105.1 million new shares at HK$29.62 each. The placing price represents a 6.5 per cent discount compared with Monday’s closing price of HK$31.68, according to its filing with the Hong Kong stock exchange on Tuesday. The...

Economics

3 w. ago How AI, quantum and space technologies will define the Asian century

History rarely announces its turning points. More often, we wake up to find that the world we assumed was fixed has begun to shift beneath our feet. That is happening now. Artificial intelligence, quantum technologies and space infrastructure are advancing at a pace that stretches our political instincts – even our imagination. Each is transformative on its own. Together, they are becoming the new architecture of global power, an engine that will determine which nations shape the century ahead...

Technology

last month China’s clinical trial capacity matches US, attracts more global pharma firms

China’s growing pipeline of novel drug candidates is expected to draw increased attention from global pharmaceutical companies and investors scouting for licensing opportunities, as the country’s clinical trial capacity has expanded to match those in the US. That assessment was made by Shanghai-based Helen Chen, Greater China managing partner at L.E.K. Consulting, one of the most respected analysts in the mainland’s life sciences industry. “There is increased interest from multinational...

Politics